Influence of dosing regimen on alprazolam and metabolite serum concentrations and tolerance to sedative and psychomotor effects
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
The relationships between alprazolam and metabolite concentrations and CNS effects were determined in a double-blind placebo controlled four-way crossover trial in 16 normal male volunteers. Active drug treatments consisted of 4-day regimens of 4 mg alprazolam PO daily as 2 mg bid., 1 mg qid, and 0.25 mg each hour. On days 1 and 4, the kinetics, sedative and psychomotor effects were evaluated. Plasma concentrations of the 4- and alpha-hydroxy metabolites of alprazolam were less than 10% of unchanged alprazolam levels on both days. Accumulation of these metabolites and alprazolam was dependent on alprazolam half-life (11.6 h). Acute and chronic tolerance to the sedative and psychomotor effects was observed with all active drug treatments. All alprazolam treatments resulted in significantly greater sedation than placebo on days 1 and 4. However, on day 4, sedation was 16-36% less than observed on day 1, despite plasma concentrations 1.4-2.76 times the day 1 concentrations. Sedation from alprazolam was reduced in each successive study phase, suggesting a tolerance which was sustained during the 10-day washout between phases. By day 4, psychomotor performance was not different from placebo, indicating more complete development of tolerance than occurred for the sedative effect. Sedation and psychomotor impairment on day 1 were greatest with 2 mg alprazolam bid. During the initiation of therapy, the patient will likely experience less sedation and psychomotor impairment with smaller, more frequent doses. Since tolerance develops to these effects, the advantage of more frequent dosing regimen dissipates by the 4th day.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tolerance to some side effects of BZDs can also develop.”
From Benzodiazepines in epilepsy: Pharmacology and pharmacokinetics (2008) · cites this paper as [195]
In the citing paper
“The onset of tolerance to the sedative effects of BZDs usually occurs within 1-2 weeks (194,195).”
From Benzodiazepines in epilepsy: Pharmacology and pharmacokinetics (2008) · cites this paper as [195]
Citations
Cites
Statistical principles in experimental design.
Winer, B. J. (1962) · McGraw-Hill Book Company · doi:10.1037/11774-000 · Cited by 26,755
Statistical Principles in Experimental Design
Myers, J. L., & Winer, B. J. (1964) · The American Journal of Psychology · doi:10.2307/1419292 · Cited by 8,058
Manual for the Wechsler Adult Intelligence Scale.
Wechsler, D. (1955) · Psychological Corp. eBooks · Cited by 4,941
Chouinard, G., Annable, L., Fontaine, R., & Solyom, L. (1982) · Psychopharmacology · doi:10.1007/bf00464571 · Cited by 256
Sedative-hypnotics and human performance
Johnson, L. C., & Chernik, D. A. (1982) · Psychopharmacology · doi:10.1007/bf00435262 · Cited by 206
Comparison of Alprazolam, Imipramine, and Placebo in the Treatment of Depression
Feighner, J. P. (1983) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1983.03330460039029 · Cited by 203
Sedative-hypnotics and human performance.
Johnson, L. C., & Chernik, D. A. (1981) · PsycEXTRA Dataset · doi:10.1037/e477732004-001 · Cited by 199
Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration
Smith, R. B., Kroboth, P. D., VanderLugt, J. T., Phillips, J. P., & Juhl, R. P. (1984) · Psychopharmacology · doi:10.1007/bf00431449 · Cited by 117
Self-citationAlprazolam Kinetics in the Elderly: Relation to Antipyrine Disposition
Greenblatt, D. J. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790030057007 · Cited by 104
Comparative pharmacokinetics and pharmacodynamics of lorazepam, alprazolam and diazepam
Ellinwood, E. H., Heatherly, D. G., Nikaido, A. M., Bjornsson, T. D., & Kilts, C. D. (1985) · Psychopharmacology · doi:10.1007/bf00427897 · Cited by 86
Research works printed but not linked: 3
- Dixon WJ, editor (1983) BMPD Statistical Software. University of California Press, Los Angeles
- Fabre LF, Mclendon DM (1980) A double-blind study comparing the efficacy and safety of alprazolam with imipramine and placebo in primary depression. Curr Ther Res Clin Exp 27:474–482
- SAS Institute Inc (1985) SAS user's Guide: Statistics, Version 5 Edition. Cary, NC
Cited by
Benzodiazepines in epilepsy: Pharmacology and pharmacokinetics
Riss, J., Cloyd, J., Gates, J., & Collins, S. (2008) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2008.01004.x · Cited by 511
Clinical Pharmacokinetics of Alprazolam: Therapeutic Implications
Greenblatt, D. J., & Wright, C. E. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199324060-00003 · Cited by 352
Pharmacodynamics in Older Adults: A Review
Bowie, M. W., & Slattum, P. W. (2007) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2007.10.001 · Cited by 266
Greenblatt, D. J., Harmatz, J. S., & Shader, R. I. (1991) · Clinical Pharmacokinetics · doi:10.2165/00003088-199121030-00002 · Cited by 182
Greenblatt, D. J., Harmatz, J. S., & Shader, R. I. (1991) · Clinical Pharmacokinetics · doi:10.2165/00003088-199121040-00003 · Cited by 177
Metadata
- Authors
- Smith, R. B., & Kroboth, P. D.
- Affiliations
- University of Pittsburgh (US)
- ORCID
- Smith, R. B.
- Venue
- Psychopharmacology
- Published
- 1987-09
- Volume
- 93
- Issue
- 1
- Pages
- 105-112
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W1984291639
- Cited by
- 76
- References
- 20
- Citations by year
- 2024: 1 · 2016: 1 · 2014: 1 · 2013: 1
- FWCI
- 6.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Sedative Agents
- Keywords
- alprazolam, dosing regimen, drug tolerance, sedation, psychomotor impairment, plasma drug concentration, drug accumulation, half-life, benzodiazepines, dosing frequency
- MeSH terms
- Adult, Alprazolam, Arousal, Biotransformation, Clinical Trials as Topic, Dose-Response Relationship, Drug, Double-Blind Method, Drug Tolerance, Humans, Kinetics, Male, Metabolic Clearance Rate, Middle Aged, Psychomotor Performance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.